Alamar Biosciences and ALZpath Announce Collaboration Centered on Furthering Alzheimer’s Disease Research
The pTau217 antibody helps pinpoint pathological changes related to the disease.
In an effort to further progress neurodegenerative disease research, Alamar Biosciences, a precision proteomics company, and ALZpath, a diagnostic solutions provider for the Alzheimer’s disease space, have signed a strategic supply agreement.1
The partnership is centered around the ALZpath pTau217 (phosphorylated tau at position 217) antibody, which the parties describe as an essential component for examining Alzheimer’s alongside other neurodegenerative disorders. ALZpath pTau217 is able to provide researchers with a tool that recognizes any pathological changes related to the disease.
Per the deal, Alamar Biosciences plans to use the pTau217 antibody in its NULISAqpcr pTau-217 assay and in its multiplexed NULISAseq CNS Disease Panel 120. This collaboration brings Almar’s NULISA platform and ALZpath’s Alzheimer’s disease diagnostics capabilities to the forefront, as they look to further R&D in the space.
“We are excited to collaborate with ALZpath to provide this ultra-sensitive pTau217 assay,” commented Dr. Yuling Luo, founder, chairman, and CEO of Alamar Biosciences. “The incorporation of the ALZpath antibody into the NULISA platform provides researchers with an automated solution for both single-plex and multiplexed analysis in CNS disease research.”
A study published in JAMA Neurology2 recently revealed results surrounding the ALZpath pTau217 assay. It suggested that the ultra-sensitive immunoassay showed high diagnostic accuracy when it came to highlighting elevated levels of amyloid in the brain.
References
1. Alamar Biosciences And ALZpath, Inc. Announce Strategic Supply Agreement For PTau217 Antibody To Advance Alzheimer’s Disease Research. Alamar Biosciences. News release. February 29, 2024. Accessed March 5, 2024. https://alamarbio.com/alamar-biosciences-and-alzpath-inc-announce-strategic-supply-agreement-for-ptau217-antibody-to-advance-alzheimers-disease-research/
2. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. Published online January 22, 2024. doi:10.1001/jamaneurol.2023.5319
Elevate Your Commercial Operations with Close-up CRM
September 6th 2024Discover a powerful, cost-effective, and robust CRM platform that maximizes your budget. Seamlessly integrate data from any source, streamline marketing efforts, and optimize HCP promotion, key account management, and digital marketing campaigns. Reduce CRM costs and reallocate funds to enhance data analytics, market research, and human capital, boosting overall commercial operations impact.
AI-Enabled Pharma CRM Driving Intelligent Customer Engagement
September 6th 2024Discover our unparalleled CRM solution that integrates AI/ML for enhanced stability, security, and performance. Leverage our team of 1000+ experts and 25K+ data provider partners. Our cloud-based SaaS model allows rapid global deployment and scalability, while our clean UX focuses on intuitive AI experience and rapid user adoption. Ensure swift 80% physician onboarding with our intuitive AI platform, speeding strategic integration.
